Progression of Kidney Disease: Diagnosis and Management

Evidence-Based Nephrology

Volumn , Issue , 2009, Pages 309-322

  Agarwal, Anil K ^a   Haddad, Nabil ^a   Hebert, Lee A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Algorithm 1. Initial antihypertensive therapy; Chronic kidney disease and chronic renal failure; Correction of anemia by erythropoietin stimulating agents (ESAs); Kidney disease progression; Recommendation 2: ACE inhibitor; Therapy of natural progression

Indexed keywords

EID: 74849102608     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303391.ch30     Document Type: Chapter

References (115)

1. Haddad N, Brown C, Hebert LA. Retarding progression of kidney disease In:Feehally J, Floege J, Johnson RJ, editors, Comprehensive Clinical Nephrology, 3rd edn. Mosby/Elsevier, Philadelphia, 2007, p 823-830.
2. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Hebert LA. Management of glomerular proteinuria:a commentary. J Am Soc Nephrol 2003; 14: 3217-3232.
3. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS, Jr., Rovin BH. Renoprotection:one or many therapies? Kidney Int 2001; 59: 1211-1226.
4. Davis CL. Evaluation of the living kidney donor:current perspectives. Am J Kidney Dis 2004; 43: 508-530.
5. Novick AC, Gephardt G, Guz B, Steinmuller D, Tubbs RR. Long-term follow-up after partial removal of a solitary kidney. N Engl J Med 1991; 325: 1058-1062.
6. Bay WH, Hebert LA. The living donor in kidney transplantation. Ann Intern Med 1987; 106: 719-727.
7. Praga M, Hernandez E, Herrero JC, Morales E, Revilla Y, Diaz-Gonzalez R et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 2111-2118.
8. Hebert LA, Kusek JW, Greene T, Adodoa LY, Jones CA, Levey AS et al. Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997; 30: 428-435.
9. Baldwin DS. Chronic glomerulonephritis:nonimmunologic mechanisms of progressive glomerular damage. Kidney Int 1982; 21: 109-120.
10. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification offocal segmental glomerulosclerosis:a working proposal. Am J Kidney Dis 2004; 43: 368-382.
11. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease:results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2005; 165: 947-953.
12. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE et al. Progression of chronic kidney disease:the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition:a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
13. Branten AJ, van den Born J, Jansen JL, Assmann KJ, Wetzels JF. Familial nephropathy differing from minimal change nephropathy and focal glomerulosclerosis. Kidney Int 2001; 59: 693-701.
14. Moghazi S, Jones E, Schroepple J, Arya K, McClellan W, Hennigar RA et al. Correlation of renal histopathology with sonographic findings. Kidney Int 2005; 67: 1515-1520.
15. Rigalleau V, Lasseur C, Raffaitin C, Beauvieux MC, Barthe N, Chauveau P et al. Normoalbuminuric renal-insufficient diabetic patients:a lower-risk group. Diabetes Care 2007; 30: 2034-2039.
16. Appel LJ, Wright JT, Greene T, Kusek JW, Lewis JB, Wang X et al. Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans. Arch Intern Med 2008; 168: 832-839.
17. Shidham G, Hebert LA. Controversies in nephrology. Timed urine collections are not needed to measure urine protein excretion in clinical practice. Am J Kidney Dis 2006; 47: 8-14.
18. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(Suppl 291): S1-S290.
19. Birmingham DJ, Rovin BH, Shidham G, Nagaraja HN, Zou X, Bissell M et al. Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int 2007; 72: 865-870.
20. Birmingham DJ, Rovin BH, Shidham G, Bissell M, Nagaraja HN, Hebert LA et al. Relationship between albuminuria and total proteinuria in SLE nephritis:diagnostic and therapeutic implications. Clin J Am Soc Nephrol 2008. [Epub ahead of print.]
21. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function:measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
22. Hebert LA, Nori U, Hebert PL. Measured and estimated glomerular filtration rate. N Engl J Med 2006; 355: 1068. [Authorreply, 355:1069-1070.]
23. Macdonald J, Marcora S, Jibani M, Roberts G, Kumwenda M, Glover R et al. GFR estimation using cystatin C is not independent of body composition. Am J Kidney Dis 2006; 48: 712-719.
24. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cys-tatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease:data from the Heart and Soul Study. Circulation 2007; 115: 173-179.
25. Brosius FC, III, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease:a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group:developed in collaboration with the National Kidney Foundation. Circulation 2006; 114: 1083-1087.
26. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl 2003; 87: S24-S31.
27. Levey AS, Mulrow CD. An editorial update:what level of blood pressure control in chronic kidney disease? Ann Intern Med 2005; 143: 79-81.
28. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ et al. The effect of a lower target blood pressure on the progression of kidney disease:long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 2005; 142: 342-351.
29. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial:clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027-3037.
30. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291-1297.
31. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2):multicentre, randomised controlled trial. Lancet 2005; 365: 939-946.
32. Hebert CJ, Shidham G, Hebert LA. Should the target for blood pressure control specify both a systolic and a diastolic component? Curr Hypertens Rep 2005; 7: 360-362.
33. Verberk WJ, Kroon AA, Kessels AG, deLeeuw PW. Home blood pressure measurement:a systematic review. J Am Coll Cardiol 2005; 46: 743-751.
34. Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension 2008; 51: 55-61.
35. Levey AS, Uhlig K. Which antihypertensive agents in chronic kidney disease? Ann Intern Med 2006; 144: 213-215.
36. Hebert LA, Rovin BH, Hebert CJ. The design of ALLHAT may have biased the study's outcome in favor of the diuretic cohort. Nat Clin Pract Nephrol 2007; 3: 60-61.
37. Kjeldsen SE, Julius S, Mancia G, McInnes GT, Hua T, Weber MA et al. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients:the VALUE trial. J Hypertens 2006; 24: 1405-1412.
38. Hebert LA, Rovin BH, Hebert CJ. Response to Dr. Brenner's comments. J Am Soc Nephrol 2004; 15: 1356-1357.
39. Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction:unraveling the ARB-MI paradox. Circulation 2006; 114: 838-854.
40. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers:a quantitative overview. Hypertension 2007; 50: 181-188.
41. Rovin BH, Hebert LA. Thiazide diuretic monotherapyfor hypertension:diuretic's dark side just got darker. Kidney Int 2007; 72: 1423-1426.
42. Esnault VL, Ekhlas A, Delcroix C, Moutel MG, Nguyen JM. Diuretic and enhanced sodium restriction results in improved antiprotein-uric response to RAS blocking agents. J Am Soc Nephrol 2005; 16: 474M81.
43. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR et al. Efficacy and safety of benazepril in advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140.
44. Hebert LA. Optimizing ACE inhibitor therapy for CKD. N Engl J Med 2006; 354: 189-191.
45. Tu K, Gunraj N, Mamdani M. Is ramipril really better than other angiotensin-converting enzyme inhibitors after acute myocardial infarction? Am J Cardiol 2006; 98: 6-9.
46. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005; 68: 2829-2836.
47. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes:systematic review and metaanalysis. Lancet 2005; 366: 2026-2033.
48. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69: 913-919.
49. Wilmer WA, Hebert LA, Lewis EJ, Rohde RD, Whittier F, Cattran D et al. Remission of nephrotic syndrome in type 1 diabetes:long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999; 34: 308-314.
50. So WY, Ma RC, Ozaki R, Tong PC, Ng MC, Ho CS et al. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients:interaction with ACE insertion/deletion polymorphism. Kidney Int 2006; 69: 1438-1443.
51. Haddad N, Rajan J, Agarwal A, et al. In chronic kidney disease ACE inhibition therapy suppresses plasma aldosterone levels better than angiotensin receptor blocker. J Am Soc Nephrol 2005; 10: 616A.
52. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190-1198.
53. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan:a doubleblind, randomized, prospective study. J Am Soc Nephrol 2005; 16: 3038-3045.
54. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167-1176.
55. Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008; 19: 771-779.
56. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease:pathophysiologyandindications. Kidney Int 2005; 67: 799-812.
57. Nakao N, Yoshimura A, Morita H, Takeda M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE):a randomised controlled trial. Lancet 2003; 361: 117-124.
58. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
59. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880-886.
60. Khosla N, Bakris GL. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol 2006; 1: 229-235.
61. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes:the BENEDICT study. J Am Soc Nephrol 2006; 17: S90-S97.
62. PROCOPA. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease:a randomized double-blind trial. J Hypertens 2002; 20: 729-737.
63. Jamerson KA, Bakris GL, Wun CC, Dahlof B, Lefkowitz M, Manfreda S et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial:the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004; 17: 793-801.
64. Teixeira SR, Tappenden KA, Carson L, Jones R, Prabhudesai M, Marhsall WP et al. Isolated soy protein consumption reduces urinary albumin excretion and improves the serum lipid profile in men with type 2 diabetes mellitus and nephropathy. J Nutr 2004; 134: 1874-1880.
65. Levey AS, Greene T, Sarnak MJ, Wang X, Beck GJ, Kusek JW et al. Effect of dietary protein restriction on the progression of kidney disease:long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 2006; 48: 879-888.
66. Jones-Burton C, Mishra SI, Fink JC, Brown J, Gossa W, Bakris GL et al. An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease. Am J Nephrol 2006; 26: 268-275.
67. Hebert LA, Greene T, Levey AS, Falkenhain ME, Klahr S. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003; 41: 962-971.
68. Wenzel UO, Hebert LA, Stahl RAK, Krenz I. My doctor said I should drink a lot! Recommendations for fluid intake in patients with chronic renal disease. Clin J Am Soc Nephrol 2006; 1: 344-346.
69. Wang X, Lewis J, Appel L, Cheek D, Contreras G, Faulkner M et al. Validation of creatinine-based estimates of GFR when evaluating risk factors in longitudinal studies of kidneydisease. J Am Soc Nephrol 2006; 17: 2900-2909.
70. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults:findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
71. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140.
72. Tonelli M. Do statins protect the kidney by reducing proteinuria? Ann Intern Med 2006; 145: 147-149.
73. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis 2004; 44: 832-839.
74. Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes:results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005; 45: 485-493.
75. Khanna B, Valentine C, Nagaraja H, et al. Fenofibrate (FF)-induced increase in serum creatinine (SCr) in chronic kidney disease (CKD) does not appear to be the result of nephrotoxicity or increased creatinine production. National Meeting, American Society of Nephrology, San Diego, 2006.
76. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis 2005; 45: 2-14.
77. Chang JW, Yang WS, Min WK, Lee SK, Park JS, Kim SB. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 2002; 39: 1213-1217.
78. D'Amico G. Statins and renal diseases:from primaryprevention to renal replacement therapy. J Am Soc Nephrol 2006; 17: S148-S152.
79. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:the ASTEROID trial. JAMA 2006; 295: 1556-1565.
80. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006; 97: 61-67.
81. Calhoun DA. Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis 2006; 48: 387-396.
82. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542.
83. Verhamme K, Mosis G, Dieleman J, Stricker B, Sturkenboom M. Spironolactone and risk of upper gastrointestinal events:population based case-control study. BMJ 2006; 333: 330.
84. Beevers DG. The end of beta blockers for uncomplicated hypertension? Lancet 2005; 366: 1510-1512.
85. Messerli FH, Bangalore S. Beta-blocker therapy in hypertension:a need to pause and reflect. J Am Coll Cardiol 2008; 51:517-518 (reply).
86. Giles TD, Bakris GL, Weber MA. Beta-blocker therapy in hypertension:aneed to pause and reflect. J Am Coll Cardiol 2008; 51: 516-517. (author reply, 51:517-518.)
87. Freedman DM, Sigurdson AJ, Rajaraman P, Doody MM, Linet MS, Ron E. The mortality risk of smoking and obesity combined. Am J Prev Med 2006; 31: 355-362.
88. Grune T, Sommerburg O, Siems WG. Oxidative stress in anemia. Clin Nephrol 2000; 53: S18-S22.
89. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-95.
90. Chong ZZ, Kang JQ, Maiese K. Angiogenesis and plasticity:role of erythropoietin in vascular systems. J Hematother Stem Cell Res 2002; 11: 863-871.
91. Kuriyama S, Hopp L, Yoshida H, Hikita M, Tomonari H, Hashimoto T et al. Evidence for amelioration of endothelial cell dysfunction by erythropoietin therapy in predialysis patients. Am J Hypertens 1996; 9: 426-431.
92. Breyer JA, Bain RP, Evans JK, Nahman NS, Jr., Lewis EJ, Cooper M et al. Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. The Collaborative Study Group. Kidney Int 1996; 50: 1651-1658.
93. Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 1997; 40: 405-411.
94. Muirhead N. The rationale for early management of chronic renal insufficiency. Nephrol Dial Transplant 2001; 16(Suppl 7): 51-56.
95. Klahr S. Prevention of progression of nephropathy. Nephrol Dial Transplant 1997; 12(Suppl 2): 63-66.
96. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995; 123: 754-762.
97. Iseki K, Ikemiya Y, Iseki C, Takishita S. Haematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant 2003; 18: 899-905.
98. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy:the RENAAL study. Kidney Int 2003; 63: 1499-1507.
99. Cusick M, Chew EY, Hoogwerf B, Agron E, Wu L, Lindley A et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), report no. 26. Kidney Int 2004; 66: 1173-1179.
100. Jungers P, Choukroun G, Oualim Z, Robino C, Nguyen AT, Man NK. Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients. Nephrol Dial Transplant 2001; 16: 307-312.
101. Dean BB, Dylan M, Gano A, Jr., Knight K, Ofman JJ, Levine BS. Erythropoiesis-stimulating protein therapy and the decline of renal function:a retrospective analysis of patients with chronic kidney disease. Curr Med Res Opin 2005; 21: 981-987.
102. Tapolyai M, Kadomatsu S, Perera-Chong M. rHu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal decline. BMC Nephrol 2003; 4: 3.
103. Roth D, Smith RD, Schulman G, Steinman TI, Hatch FE, Rudnick MR et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777-784.
104. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997; 77: 176-185.
105. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function:a randomized controlled trial. Kidney Int 2004; 66: 753-760.
106. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease:2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471-530.
107. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner RM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66: 1131-1138.
108. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410.
109. Persson F, Rossing P, Schjoedt KJ, Juhl T, Tarnow L, Stehouwer CD et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008; 73: 1419-1425.
110. Parving HH, Lewis JB, Lewis EJ, et al. Aliskiren in the evaluation of proteinuriaindiabetes (AVOID). J Am Soc Nephrol 2007; 18:SA-P01051 (abstract).
111. Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 2004; 164: 1519-1524.
112. Fored CM, Nyren O. Acetaminophen, aspirin, and renal failure (letter). N Engl J Med 2002; 346: 1588-1589.
113. Isnard Bagnis C, Deray G, Baumelou A, Le Quintrec M, Vanherweghem JL. Herbs and the kidney. Am J Kidney Dis 2004; 44: 1-11.
114. Rangan GK, Pippin JW, Coombes JD, Couser WG. C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria. Kidney Int 2005; 67: 492-503.
115. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P et al. Antiproteinuric effect of oral paricalcitol in chronic kidneydisease. Kidney Int 2005; 68: 2823-2828.